Payment overview · 2025
General Payments
$3,534.54
117 reported records · 23 companies
Healthcare provider profile · identity verified
Mark Michailovich Aronov, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WEST BLOOMFIELD, MI · NPI 1730390212
Verified facts
What the public records show
CMS Open Payments records show Mark Michailovich Aronov, DO received $3,534.54 in general payments during 2025 across 117 reported records.
PFIZER INC. accounted for 48.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,717.50 | 48.6% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $416.81 | 11.8% | 29 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $271.13 | 7.7% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $261.94 | 7.4% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.69 | 6.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $141.67 | 4.0% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $74.94 | 2.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.63 | 1.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.65 | 1.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.30 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.41 | 1.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.34 | 1.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.21 | 0.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.32 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.41 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.72 | 0.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.30 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.64 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.08 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.16 | 0.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.90 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.11 | 0.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.68 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,034.54 | 116 |
| Consulting Fee | $1,500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $1,663.58 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $237.65 | 17 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $237.65 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $210.69 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $179.16 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.63 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $141.67 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $131.91 | 12 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $74.94 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.30 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.41 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.94 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.94 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.94 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 150 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 190 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 35 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 42 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
136 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
190 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1137 | 341 |
| Lisinopril | Lisinopril | 478 | 124 |
| Metformin Hcl | Metformin Hcl | 447 | 136 |
| Losartan Potassium | Losartan Potassium | 439 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 117 |
| Omeprazole | Omeprazole | 356 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 65 |
| Potassium Chloride | Potassium Chloride | 200 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 63 |
| Ozempic | Semaglutide | 190 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 87 |
| Trazodone Hcl | Trazodone Hcl | 179 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 52 |
| Simvastatin | Simvastatin | 177 | 45 |
| Allopurinol | Allopurinol | 173 | 43 |
| Nifedipine Er | Nifedipine | 166 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 62 |
| Furosemide | Furosemide | 155 | 50 |
| Eliquis | Apixaban | 150 | 42 |
| Jardiance | Empagliflozin | 146 | 42 |
| Carvedilol | Carvedilol | 140 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 44 |
| Trulicity | Dulaglutide | 136 | 30 |
| Gabapentin | Gabapentin | 133 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 32 |
| Farxiga | Dapagliflozin Propanediol | 112 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 34 |
| Prednisone | Prednisone | 106 | 67 |
| Mounjaro | Tirzepatide | 105 | 17 |
| Sertraline Hcl | Sertraline Hcl | 101 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 26 |
| Finasteride | Finasteride | 98 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 24 |
| Montelukast Sodium | Montelukast Sodium | 93 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 31 |
| Alendronate Sodium | Alendronate Sodium | 84 | 25 |
| Ezetimibe | Ezetimibe | 83 | 32 |
| Chlorthalidone | Chlorthalidone | 81 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 19 |
| Methylprednisolone | Methylprednisolone | 72 | 67 |
| Valsartan | Valsartan | 72 | 19 |
| Spironolactone | Spironolactone | 71 | 28 |
| Bumetanide | Bumetanide | 70 | 26 |
| Famotidine | Famotidine | 66 | 22 |
| Mirtazapine | Mirtazapine | 66 | 27 |
| Januvia | Sitagliptin Phosphate | 63 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Atenolol | Atenolol | 56 | 19 |
| Bupropion Xl | Bupropion Hcl | 55 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 17 |
| Irbesartan | Irbesartan | 53 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 51 | 22 |
| Azithromycin | Azithromycin | 49 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Rybelsus | Semaglutide | 48 | 14 |
| Glipizide Er | Glipizide | 47 | 15 |
| Novolog Flexpen | Insulin Aspart | 47 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 14 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Celecoxib | Celecoxib | 44 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | 17 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Ibuprofen | Ibuprofen | 37 | 20 |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 11 |
| Meloxicam | Meloxicam | 36 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Donepezil Hcl | Donepezil Hcl | 34 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Colchicine | Colchicine | 29 | 15 |
| Kerendia | Finerenone | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Topiramate | Topiramate | 26 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Meclizine Hcl | Meclizine Hcl | 23 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | 11 |
| Torsemide | Torsemide | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Benzonatate | Benzonatate | 13 | 11 |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Curity Alcohol Preps | Alcohol Antiseptic Pads | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,534.54 · 117 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, COMIRNATY, CONTRAVE, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, XIFAXAN, YUPELRI, Yeztugo, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error